PCVX News and Press, Vaxcyte Inc. From 11/06/23

-- Completed Successful End-of-Phase 2 Meeting with FDA for VAX-24; Topline Phase 3 Data in Adults Expected in 2025 -- -- Received FDA Clearance of VAX-31 Adult IND Application; Phase 1/2 Study Initiation Expected This Quarter and Topline Data Expected in the Second Half of 2024 -- ...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Vaxcyte Inc. (PCVX) is expected to report $-0.79 for Q3 2023

-- Company Expects to Initiate VAX-31 Phase 1/2 Study in Healthy Adults This Quarter-- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-31 Phase 1/2 Study Expected in the Second Half of 2024 -- -- VAX-31 is a 31-Valent Pneumococcal Conjugate Vaccine De...

2023-10-16 18:25:10 ET Summary Vaxcyte, Inc. is making substantial progress with its vaccine candidate VAX-24 for the prevention of invasive pneumococcal disease as evidenced by trial data. Obtained positive immunogenicity data from its phase 2 study in adults for prevention of IP...

2023-10-16 10:34:11 ET More on Vaxcyte Strong Financials And Pipeline Position Vaxcyte For Success Seeking Alpha’s Quant Rating on Vaxcyte Historical earnings data for Vaxcyte Financial information for Vaxcyte For further details see: Vaxcy...

-- New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations -- -- Expanded Collaboration Builds on Vaxcyte’s Current Strategy to Conduct Initial Commercial Launch of VAX-24 in Adult...

2023-09-28 13:35:36 ET More on Vaxcyte Strong Financials And Pipeline Position Vaxcyte For Success Seeking Alpha’s Quant Rating on Vaxcyte Historical earnings data for Vaxcyte Financial information for Vaxcyte For further details see: Vaxcy...

SAN CARLOS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fires...

2023-09-14 13:21:48 ET Summary Sutro is developing mainly antibody-drug conjugates to address solid tumors. Their flagship molecule has shown both encouraging efficacy and concerning toxicity. The company has strengthened their balance sheet strategically, removing the short-t...